EGFR and Miyoshi myopathy: Clinical evaluation of ERBB1/EGFR targeting therapeutics in MM patients would benefit from integrated biomarker research to determine if MM cells display or acquire any ERBB1/EGFR mutations that may affect treatment outcomes.